

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 3 July 2021

Situation Report No. 263 - Kingdom of Bahrain  
4<sup>th</sup> of July, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	182,319,261	3,954,324	11,022,816	217,304
<b>New</b>	361,149 (as 2 July 2021)	8,053 (as 2 July 2021)	37,031 (as 1 July 2021)	516 (as 1 July 2021)

## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
<b>Total</b>	266,286	262,552	1,358	2,376	82	5,077,225	1,071,685	996,404
<b>New</b>	146	390	2	-	-	12,280	-	-

## HIGHLIGHTS and USEFULL LINKS

- **MOH:** Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 3 July 2021 for the first dose (1,071,685) and for the second dose (996,404)
- **MOH:** The Minister of Health welcomes Dr. Tasneem Atatreh on the first day of officially assuming her duties as the first permanent Representative of the organization for the Eastern Mediterranean Region in the Kingdom
- **MOH:** The National Medical Taskforce for Combating the Coronavirus (COVID-19) highlights measures taken to mitigate the spread of COVID-19.
- **MOH:** New guidelines have been introduced for businesses as they reopened doors yesterday to customers after a decline in Covid-19 cases over the last one month; <https://www.gdnonline.com/Details/950065>
- **MOH:** Guidelines for COVID-19 Alert Level Traffic Light System: [https://healthalert.gov.bh/uploads/e2rlnl5n\\_1hl.pdf](https://healthalert.gov.bh/uploads/e2rlnl5n_1hl.pdf)
- **MOH:** Daily COVID-19 updates on MoH website: <https://www.moh.gov.bh/>

- **WHO:** Implementation guidance for assessments of frontline service readiness: strengthening real-time monitoring of health services in the context of the COVID-19 pandemic: [https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF\\_assessment-Frontline\\_services-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF_assessment-Frontline_services-2021.1)
- **WHO:** Updated guidance on the use of Moderna mRNA-1273 vaccine against COVID-19: <https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19>
- **WHO:** Protocol template to be used as template for observational study protocols for cohort event monitoring (CEM) for safety signal detection after vaccination with COVID-19 vaccines : <https://www.who.int/publications/i/item/9789240027398>
- **WHO:** Protocol template to be used as template for observational study protocols for sentinel surveillance of adverse events of special interest (AESIs) after vaccination with COVID-19 vaccines: <https://www.who.int/publications/i/item/9789240029507>
- **WHO:** An Ethical Framework for WHO's work in the ACT-Accelerator: [https://www.who.int/publications/i/item/WHO-2019-nCoV-ACT-Accelerator-Ethical\\_framework-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-ACT-Accelerator-Ethical_framework-2021.1)
- **WHO:** WHO BioHub System: <https://www.who.int/initiatives/who-biohub/>
- **WHO:** Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF\\_assessment-Products-2020.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1)
- **WHO:** Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based\\_international\\_travel-Assessment\\_tool-2020.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1)
- **WHO:** Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: [https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages)

## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAli5@health.gov.bh](mailto:NAli5@health.gov.bh)
- International Health Regulations focal person is Dr. Adel Salman Alsayyad; email: [ASayyad@health.gov.bh](mailto:ASayyad@health.gov.bh)
- International Health Regulations, Dr Afaf Merza Ahmed Ali Mohamed; email: [AAli9@health.gov.bh](mailto:AAli9@health.gov.bh)





